- Home
- GMRE vs KURA Comparison
GMRE vs KURA Comparison
Compare GMRE & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMRE
- KURA
- Stock Information
- Founded
- GMRE 2011
- KURA 2014
- Country
- GMRE United States
- KURA United States
- Employees
- GMRE N/A
- KURA N/A
- Industry
- GMRE Real Estate Investment Trusts
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMRE Real Estate
- KURA Health Care
- Exchange
- GMRE Nasdaq
- KURA Nasdaq
- Market Cap
- GMRE 485.5M
- KURA 492.9M
- IPO Year
- GMRE N/A
- KURA N/A
- Fundamental
- Price
- GMRE $6.33
- KURA $6.42
- Analyst Decision
- GMRE Buy
- KURA Strong Buy
- Analyst Count
- GMRE 3
- KURA 12
- Target Price
- GMRE $10.38
- KURA $24.50
- AVG Volume (30 Days)
- GMRE 712.1K
- KURA 1.2M
- Earning Date
- GMRE 05-07-2025
- KURA 05-01-2025
- Dividend Yield
- GMRE 12.31%
- KURA N/A
- EPS Growth
- GMRE N/A
- KURA N/A
- EPS
- GMRE 0.03
- KURA N/A
- Revenue
- GMRE $138,220,000.00
- KURA $67,991,000.00
- Revenue This Year
- GMRE $4.48
- KURA $171.90
- Revenue Next Year
- GMRE $4.57
- KURA $60.51
- P/E Ratio
- GMRE $197.91
- KURA N/A
- Revenue Growth
- GMRE N/A
- KURA N/A
- 52 Week Low
- GMRE $6.06
- KURA $5.41
- 52 Week High
- GMRE $10.46
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- GMRE 31.38
- KURA 55.97
- Support Level
- GMRE $6.16
- KURA $5.56
- Resistance Level
- GMRE $6.43
- KURA $5.84
- Average True Range (ATR)
- GMRE 0.17
- KURA 0.36
- MACD
- GMRE 0.01
- KURA 0.05
- Stochastic Oscillator
- GMRE 32.54
- KURA 89.52
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.